Browse the full record of transactions filed by Demurjian Michael, Chief Operating Officer. Insider active across 1 companies, notably Tyme Technologies, INC.. Cumulatively, 98 filings have been logged. Total volume traded: €1.5m. The latest transaction was filed on 28 June 2022 — Cession. Regulator: SEC (Form 4). All data is openly available.
25 of 98 declarations
Michael Demurjian is best known for his leadership role at TYME Technologies, Inc., where he served as Chief Operating Officer, Executive Vice President, and a director until his resignation from both management and the board in March 2019. In that capacity, he led teams involved in studies and data collection supporting regulatory submissions, including filings with the FDA. His responsibilities at TYME reflected a hands-on operating profile centered on clinical development support, regulatory coordination, and execution within a biotechnology company operating in the U.S. public markets. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000119312517240570/d431089d10ka.htm)) Prior to TYME, Demurjian co-founded Mikronite Technologies Group, Inc., a developer, licensor, and marketer of material surfacing technologies. From 1993 to 2007, he served as Director of Marketing and was responsible for building the company’s marketing function from the ground up. His work included marketing research and analysis, marketing strategy, implementation planning, and broader project, process, and vendor management. This suggests deep experience in commercialization, go-to-market planning, and organizational leadership in a technology-driven business environment. The company’s work was recognized by The Home Depot, Lowe’s, and the New Jersey Manufacturers Association, which adds evidence of market-facing execution during that period. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000119312517240570/d431089d10ka.htm)) Demurjian’s background also includes service as a manager at Luminant Biosciences LLC from its formation in 2011, reinforcing his long-standing involvement in biotech-related ventures. He earned a BA in Economics from New York University in 1986. Based on the sources reviewed, the most accurate professional summary is that he is a biotech and technology executive with experience spanning marketing leadership, operating management, and regulatory-support functions; however, I would avoid asserting any more recent title beyond the TYME role without additional verified sources. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1537917/000119312517240570/d431089d10ka.htm))